South Africa Andre Nel has been appointed as Amsterdam-based Lumicks’ new CFO.
Life science tools company Lumicks has appointed Andre Nel as its new CFO. Andre, who was born in South Africa, will be based at the company’s headquarters in Amsterdam.
“I am excited to join Lumicks as it begins to expand its operations around the world,” Andre says. “My expertise in working with life sciences companies on a global basis has prepared me well to build scalable operations that enable companies to achieve successful growth.”
He adds that he is confident that the company is “on the cusp of an accelerated growth trajectory”, and that he looks forward to working with his new colleagues to establish a firm financial foundation to support that growth.
Andre most recently served as CFO at Dante Labs. He previously spent close to seven years with Illumina, starting as CFO of the group’s EMEA operations based in Cambridge in the UK, and ending as VP of finance and a member of the global finance leadership team based in the US. Before that, he was the FD of Pfizer’s Russian Federation region, the global transformation and European decision support centre of excellence finance lead, head of financial planning and reporting for its Europe region, and finance manager for its South African region. He also served as the managing director of Union Spinning Mills in South Africa, FD and company secretary for Tridelta South Africa and Germany, and assistant audit manager of Fisher Hoffman Stride respectively.
About the appointment, Lumicks CEO Olivier Heyning says:
“We are very pleased to attract an experienced life sciences financial executive like Andre to Lumicks at this pivotal point in our growth. His seasoned expertise across large, global life science companies, including Illumina and Pfizer, will be invaluable to us as we accelerate our growth worldwide.”
He explains that, with the company’s recent successful product launches and the increasing recognition its innovative technology is receiving as a critical tool in analysing core biological processes, Andre’s financial expertise will enable the group to achieve growth plans and establish it as a leader within the life sciences industry worldwide.
